Key facts
- This page summarizes Thomas Layton Walton's Form 4 filing for BiomX Inc. (PHGE).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 14 Feb 2022, 15:24.
Thomas Layton Walton - 31 Dec 2021 Form 4 Insider Report for BiomX Inc. (PHGE)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- PHGE
- Reported as of
- 31 Dec 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Feb 2022, 15:24:48 UTC
- Prior SEC filing
- 09 Aug 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Thomas Layton Walton
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Thomas Layton Walton filed Form 4 for BiomX Inc. (PHGE) on 14 Feb 2022.
Change
- Previous filing in this sequence was filed on 09 Aug 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHGE
transaction
Common Stock, $0.0001 par value
Other
- Transaction value
- $0
- Shares
- -3,637,846
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 31 Dec 2021
- Ownership
- By SymBiosis, LLC
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PHGE
transaction
Derivative
Warrants to purchase Common Stock
Other
- Transaction value
- $0
- Shares
- -1,875,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 31 Dec 2021
- Ownership
- By SymBiosis, LLC
- Underlying class
- Common Stock
- Underlying amount
- 1,875,000
- Exercise price
- $5.00
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Thomas Layton Walton is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
The common stock and warrants to purchase common stock previously reported by the reporting person are no longer indirectly beneficially owned by such reporting person and the reporting person specifically disclaims beneficial ownership of the securities reported. The shares are directly held by SymBiosis, LLC, over which the reporting person exercises investment discretion, but does not possess voting or dispositive power.